Proteomics, Genomics & Microarrays
Advanced NGS panel improves residual AML disease detection
OGT has launched the SureSeq Myeloid MRD Panel, a next-generation sequencing (NGS) assay designed for highly sensitive detection of measurable residual disease (MRD) biomarkers in acute myeloid leukemia (AML). This panel enhances the detection of ultra-low frequency variants, including large and complex FLT3 internal tandem duplications (ITDs), which are often missed by traditional PCR-based methods.
Accurate MRD detection is essential for improving clinical research and patient management in AML. Studies show that MRD negativity is linked to better long-term survival, making sensitive detection critical for understanding remission and relapse. The SureSeq panel targets 13 key AML biomarkers, expanding the ability to characterise the disease status with unprecedented resolution.
The panel’s hybrid capture technology delivers reliable detection of complex structural variants and avoids the inaccuracies common with PCR-based enrichment. OGT’s advanced bait design ensures robust identifi cation of large FLT3-ITDs - up to 300 base pairs - providing insights that were previously diffi cult to obtain.
Designed with fl exibility in mind, the SureSeq panel supports multiple pre-optimised workfl ows that can be tailored for sensitivity, sample batching, and sequencing needs. It includes complementary bioinformatics software, Interpret, which offers customisable analysis pipelines, reducing the bioinformatics burden for labs.
Researchers have praised the panel’s performance, noting its ability to detect all variants found by comparator assays plus additional clinically relevant mutations, enabling more comprehensive MRD analysis.
More information online:
ilmt.co/PL/5jxv 64858pr@reply-direct.com Tailored human biospecimens for biomedical discovery
AMSBIO has broadened its biofluid collection and processing capabilities, now offering an extensive range of ethically sourced, customisable human blood biospecimens from both healthy and disease-state donors to support cutting-edge biomedical research.
Drawing on a diverse network of donors, AMSBIO provides high-quality samples tailored to specific demographic profiles, volumes, and processing protocols. The company’s fully licensed collection and processing facility ensures complete traceability and regulatory compliance at every step.
The expanded portfolio includes leukopaks, plasma, serum, whole blood, peripheral blood mononuclear cells (PBMCs), and isolated immune cells, each prepared to meet strict research specifications.
Unlike conventional blood banks, AMSBIO offers researchers enhanced flexibility in donor selection and consent processes - making it possible to source fully authorised samples for commercial use in applications such as drug development, cell therapy, and regenerative medicine.
Designed to accelerate research across oncology, autoimmune disorders, neurodegeneration, and other therapeutic areas, AMSBIO biospecimens provide access to well-characterised donor cohorts that align closely with study requirements.
In addition to its expanded offering, AMSBIO now provides rapid processing and overnight delivery of fresh, custom-prepared biofluids across Europe. Plans are also in place to extend this service to North America, widening access to its bespoke collection capabilities.
With decades of experience in biospecimen handling, AMSBIO remains a trusted partner for high-quality biofluid sourcing, committed to precision, compliance, and scientific excellence. More information online:
ilmt.co/PL/DR84
64427pr@reply-direct.com New spatial imaging system advances tissue proteomics research
Thermo Fisher Scientific has launched the Invitrogen™ EVOS™ S1000 Spatial Imaging System, designed to help researchers generate high-quality multiplexed images while streamlining sample processing.
The EVOS S1000 overcomes key challenges in fluorescent microscopy by enabling researchers to capture high-resolution images of multiple tissue samples in just hours. Its advanced spectral technology allows simultaneous imaging of up to nine different protein targets, minimising the need for multiple imaging rounds and preserving tissue integrity.
“Understanding tissue structure is essential for advancing treatments for solid tumours and neurodegenerative diseases,” said Trisha Dowling, Vice President and General Manager for flow and imaging technologies at Thermo Fisher Scientific. “The EVOS S1000 provides a detailed view of tissue microenvironments in their native state, helping researchers accelerate their studies and maximise insights from their samples.”
The system’s compatibility with a wide range of reagents and antibodies ensures seamless integration into existing workflows.
“Our lab manages everything from project design to imaging, so delivering high-quality results efficiently is crucial,” said Carolina Oses Sepúlveda, Researcher and Lab Manager for Spatial Proteomics at SciLifeLab Stockholm. “The EVOS S1000 gives us the flexibility to use any antibody or reagent - or even work without antibodies - reducing processing time and expanding our research capabilities.”
Now available in the United States and Europe, the EVOS S1000 Spatial Imaging System provides researchers with powerful tools to explore complex biological systems and advance disease research. More information online:
ilmt.co/PL/MKBx
64033pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
